Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Zai Lab (Shanghai) Co., Ltd.
This is a first-in-human, dose escalation trial of ZL-1201. The major aims of the study are to define the safety profile of this new drug, and to determine a recommended dose and schedule for potential additional trials.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically/cytologically confirmed, locally advanced unresectable or metastatic solid tumors and lymphomas that are refractory or intolerant to standard of care therapy, or for which no standard therapy exists.
Adequate hematologic status
Adequate coagulation function
Adequate hepatic function
Adequate renal function
You may not be if
Known active brain metastases
Red blood cells transfusion dependence
Known cardiopulmonary disease
Pregnant or breast-feeding females
Any other serious underlying medical
Clareo Health | A Trial of ZL-1201 in Subjects With Advanced Cancer
